Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to 89.0%

Gross margin was 89.0% in Q2 FY2026, down 6.7 pp from a year earlier. On a trailing-twelve-month basis it was 91.5%, down 4.8 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
89.0%-2.4 pp QoQ
Last fiscal yearDec 2025
94.1%-2.4 pp YoY
LTMJun 2026
91.5%-4.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6.7 pp——
1 year-2.4 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
94.1%
Year-over-year change
-2.4pp

Gross Margin vs competitors

How MDGL compares with its peers on the latest reported figures

  • MDGL's LTM Jun 2026 gross margin of 91.5% is the 3rd highest of the 5 companies compared; the peer median is 62.9%.
  • Its year-over-year change of -4.8 pp is the highest of 5, against a peer median of -37.1 pp.
MDGL Competitors Peer median
Gross Margin for MDGL and competitors
Company Period LTM level YoY 3-year change
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 202692.1% -7.9 pp-0.3 pp
MAZEMaze Therapeutics, Inc.LTM Mar 202692.0% -8.0 pp—
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 202691.5% -4.8 pp—
IVAInventiva S.A.FY202533.7% -66.3 pp-106.4 pp
ALTAltimmune, Inc.LTM Mar 2026-41519.4% -41619.4 pp+0.0 pp
VKTXViking Therapeutics, Inc.FY2025— ——
SGMTSagimet Biosciences Inc.FY2025— ——
Peer median (excluding MDGL) 62.9%-37.1 pp-0.3 pp

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000180.13M958.4M
Cost of Revenue0006.23M56.15M
Gross Profit000173.9M902.26M
Gross Margin———96.5%94.1%
Research & Development205.16M245.44M272.35M236.72M388.53M
Selling, General & Admin37.32M48.13M108.15M435.06M813.83M
Operating Expenses242.48M293.57M380.5M671.78M1.2B
Depreciation & Amortization405K467K527K1.1M1.51M
EBITDA(241.44M)(290.92M)(360.39M)(450.13M)(264.47M)
EBITDA Margin———-249.9%-27.6%
Operating Income(242.48M)(293.57M)(380.5M)(497.88M)(300.1M)
Operating Margin———-276.4%-31.3%
Interest Income363K2.19M19.58M46.65M37.36M
Interest Expense03.96M12.71M14.67M22.31M
Other Income / Expenses636K(1.78M)6.87M31.98M11.81M
Income Before Tax(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Pre-Tax Margin———-258.6%-30.1%
Income Tax Expense00000
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Net Margin———-258.6%-30.1%
EPS (Basic)(14.63)(17.23)(19.99)(21.90)(12.85)
EPS (Diluted)(14.63)(17.23)(19.99)(21.90)(12.85)
Weighted Avg Shares16.54M17.14M18.69M21.27M22.43M
Weighted Avg Shares (Diluted)16.54M17.14M18.69M21.27M22.43M

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.